Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...

NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.

CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide (2.4 mg) and semaglutide (2.4 ... which also fell short of the expected loss of 25%. NVO plans to file regulatory ...

Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...

CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide (2.4 mg) and semaglutide (2.4 ... which also fell short of the expected loss of 25%. NVO plans to file regulatory ...

Press release - No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the Phas ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...